carnitine palmitoyltransferase 1A
Last updated 17 Mar 2025
Meets Patient’s editorial guidelines
- DownloadDownload
- Share
- Language
- Discussion
- Ask Patient
- Audio Version
- Add to preferred sources on Google
The CPT1A gene provides instructions for making an enzyme called carnitine palmitoyltransferase 1A, which is found in the liver. This enzyme is essential for fatty acid oxidation, a multistep process that breaks down (metabolizes) fats and converts them into energy. During periods of fasting, long-chain fatty acids are an important energy source for the liver and other tissues. Within liver cells, fatty acid oxidation takes place within mitochondria, which are the energy-producing centers. Before entering mitochondria, a group of fats called long-chain fatty acids must first be attached to a substance known as carnitine. Carnitine palmitoyltransferase 1A connects carnitine to long-chain fatty acids so they can cross the inner membrane of mitochondria. Inside mitochondria, carnitine is removed from the fatty acids, and they can be metabolized to produce energy.
Video picks for GenesVideo library
Normal function
The CPT1A gene provides instructions for making an enzyme called carnitine palmitoyltransferase 1A, which is found in the liver. This enzyme is essential for fatty acid oxidation, a multistep process that breaks down (metabolizes) fats and converts them into energy. During periods of fasting, long-chain fatty acids are an important energy source for the liver and other tissues. Within liver cells, fatty acid oxidation takes place within mitochondria, which are the energy-producing centers. Before entering mitochondria, a group of fats called long-chain fatty acids must first be attached to a substance known as carnitine. Carnitine palmitoyltransferase 1A connects carnitine to long-chain fatty acids so they can cross the inner membrane of mitochondria. Inside mitochondria, carnitine is removed from the fatty acids, and they can be metabolized to produce energy.
Conditions referring to this gene or chromosome
Other names
carnitine palmitoyltransferase 1A (liver)
carnitine palmitoyltransferase I, liver
CPT1
CPT1-L
CPT1A_HUMAN
L-CPT1
Patient picks for Genes
Related patient information and medicines

Patient information leaflet
Albinism
What is albinism. Albinism is an inherited condition that leads to someone having very light skin, hair, and eyes. It happens because they have less melanin than usual in their body. Melanin gives skin, hair, and eyes their colour. Except for vision problems, most people with albinism are just as healthy as anyone else. Symptoms of albinism Signs.

Medicine leaflet
Pivmecillinam for infection
About pivmecillinam Type of medicine Penicillin antibiotic Used for Infections Also called Amdinocillin pivoxil (in US); Selexid® Available as Tablets Pivmecillinam is used to treat bacterial infections, such as some urinary tract infections. It is also used to treat infections caused by a type of germ (bacte... If you have a rare inherited blood.

Medicine leaflet
Levocarnitine
Levocarnitine is a supplement. It has been prescribed for you because your body has a shortage of carnitine. They include feeling sick (nausea), diarrhoea, and tummy (abdominal) discomfort. About levocarnitine Type of medicine A carnitine supplement Used for Carnitine deficiency Also called L-carnitine or carnitine Brands include: Bio-Carnitine®;.
Further reading and references
- carnitine palmitoyltransferase 1A; MedlinePlus, National Library of Medicine.
- Akkaoui M, Cohen I, Esnous C, Lenoir V, Sournac M, Girard J, Prip-Buus C. Modulation of the hepatic malonyl-CoA-carnitine palmitoyltransferase 1A partnership creates a metabolic switch allowing oxidation of de novo fatty acids. Biochem J. 2009 May 27;420(3):429-38. doi: 10.1042/BJ20081932.
- Balci MC, Karaca M, Selamioglu A, Korbeyli HK, Durmus A, Ak B, Kozanoglu T, Gokcay GF. A different perspective into clinical symptoms in CPT I deficiency. Mol Genet Metab Rep. 2023 Nov 30;38:101032. doi: 10.1016/j.ymgmr.2023.101032. eCollection 2024 Mar.
- Bennett MJ, Boriack RL, Narayan S, Rutledge SL, Raff ML. Novel mutations in CPT 1A define molecular heterogeneity of hepatic carnitine palmitoyltransferase I deficiency. Mol Genet Metab. 2004 May;82(1):59-63. doi: 10.1016/j.ymgme.2004.02.004.
- Bonnefont JP, Djouadi F, Prip-Buus C, Gobin S, Munnich A, Bastin J. Carnitine palmitoyltransferases 1 and 2: biochemical, molecular and medical aspects. Mol Aspects Med. 2004 Oct-Dec;25(5-6):495-520. doi: 10.1016/j.mam.2004.06.004.
- Brown NF, Mullur RS, Subramanian I, Esser V, Bennett MJ, Saudubray JM, Feigenbaum AS, Kobari JA, Macleod PM, McGarry JD, Cohen JC. Molecular characterization of L-CPT I deficiency in six patients: insights into function of the native enzyme. J Lipid Res. 2001 Jul;42(7):1134-42.
- Gobin S, Bonnefont JP, Prip-Buus C, Mugnier C, Ferrec M, Demaugre F, Saudubray JM, Rostane H, Djouadi F, Wilcox W, Cederbaum S, Haas R, Nyhan WL, Green A, Gray G, Girard J, Thuillier L. Organization of the human liver carnitine palmitoyltransferase 1 gene ( CPT1A) and identification of novel mutations in hypoketotic hypoglycaemia. Hum Genet. 2002 Aug;111(2):179-89. doi: 10.1007/s00439-002-0752-0. Epub 2002 Jul 16.
- Gobin S, Thuillier L, Jogl G, Faye A, Tong L, Chi M, Bonnefont JP, Girard J, Prip-Buus C. Functional and structural basis of carnitine palmitoyltransferase 1A deficiency. J Biol Chem. 2003 Dec 12;278(50):50428-34. doi: 10.1074/jbc.M310130200. Epub 2003 Sep 29.
- Lee K, Pritchard A, Ahmad A. Carnitine Palmitoyltransferase 1A Deficiency. 2005 Jul 27 [updated 2025 Feb 20]. In: Adam MP, Bick S, Mirzaa GM, Wallace SE, Amemiya A, editors. GeneReviews(R) [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2026. Available from http://www.ncbi.nlm.nih.gov/books/NBK1527/
- Longo N, Amat di San Filippo C, Pasquali M. Disorders of carnitine transport and the carnitine cycle. Am J Med Genet C Semin Med Genet. 2006 May 15;142C(2):77-85. doi: 10.1002/ajmg.c.30087.
- Ramsay RR, Zammit VA. Carnitine acyltransferases and their influence on CoA pools in health and disease. Mol Aspects Med. 2004 Oct-Dec;25(5-6):475-93. doi: 10.1016/j.mam.2004.06.002.
- Vockley J. Long-chain fatty acid oxidation disorders and current management strategies. Am J Manag Care. 2020 Aug;26(7 Suppl):S147-S154. doi: 10.37765/ajmc.2020.88480.
Share your thoughts or experiences with others in our patient communities.
Sign up to the Patient newsletter
Your weekly dose of clear, trustworthy health advice - written to help you feel informed, confident and in control.
By subscribing you accept our Privacy Policy. You can unsubscribe at any time. We never sell your data.

